A new treatment for uncomplicated urinary tract infections. 🦠 скачать в хорошем качестве

A new treatment for uncomplicated urinary tract infections. 🦠

A new treatment for uncomplicated urinary tract infections. 🦠 Curbsider contributor Dr. Alyssa Mancini shares her summary of this recent @fda news release as outlined in our most recent The Curbsiders Digest #53! 📰 In a recent FDA News Release, the U.S. FDA approved Pivya (pivmecillinam), a beta-lactam antibacterial tablet, for the treatment of female adults with uncomplicated urinary tract infections caused by (susceptible) Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivya’s efficacy was evaluated in 3 controlled clinical trials looking at the composite response rate, which included clinical cure and microbiological response, assessed 8-14 days after enrollment. In one of these trials, comparing Pivya to placebo, 62% of patients achieved the composite response with Pivya compared to 10% with placebo. In a trial comparing Pivya to another oral antibacterial drug (cephalexin), there was a composite response rate of 72% with Pivya compared to 76% with the comparator drug. The most common side effects of Pivya were nausea and diarrhea. (AM) Save 🛟 and share 👯with someone who needs this update!